Tysabri Review Extended Until June
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants more time to evaluate the risk management plan for the withdrawn multiple sclerosis drug.
You may also be interested in...
Tysabri Re-Launch Timing Will Depend On Outcome Of Risk Management Plan
Biogen Idec/Elan could be prepared to get the multiple sclerosis drug back on the market within weeks of re-approval.
Tysabri Re-Launch Timing Will Depend On Outcome Of Risk Management Plan
Biogen Idec/Elan could be prepared to get the multiple sclerosis drug back on the market within weeks of re-approval.
Copaxone Sales Will Continue Growth Regardless Of Tysabri Re-Launch, Teva Says
Teva expects sales of its multiple sclerosis therapy Copaxone (glatiramer)to continue to grow in 2006 regardless of whether FDA allows the re-launch of competitor Tysabri (natalizumab)